Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection
A more personalised approach to hepatitis C treatment may improve adherence and completion rates
One million people with hepatitis C in the US at high priority for treatment
Many hepatitis C patients with cirrhosis or advanced fibrosis face liver failure and liver cancer
European HIV response "falling behind" as Eastern European epidemic grows
Sofosbuvir/ledipasvir with ribavirin cures most people with hepatitis C recurrence after liver transplantation
Sofosbuvir + simeprevir shows good results for hepatitis C in real-world use
DAAs show good cure rates and liver function improvement for transplant recipients with recurrent HCV
AbbVie 3D regimen cures recurrent HCV in most liver transplant recipients without cirrhosis
